Combination of two targeted drugs for relapsed or refractory PTCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of peripheral T-cell lymphoma (PTCL), including certain subtypes like ALCL, PTCL-NOS, or others listed in the study.
- You must have had at least one previous treatment for your lymphoma. If you have ALCL, you must have already received a CD30-targeted therapy.
- You must have at least one measurable or evaluable tumor lesion, as defined by standard lymphoma criteria.
- You must be in generally good health with performance status 0–2 (able to care for yourself and be up and about).
- You must have adequate organ function, expected survival of at least 3 months, and agree to use effective contraception if you are fertile.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
This study tests whether adding a targeted drug called linperlisib to the standard chemo regimen (CHOP) is better than CHOP alone for people with newly diagnosed peripheral T-cell lymphoma. It may help shrink tumors and control the lymphoma for longer.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of two drugs, Linperlisib and Chidamide, for people with peripheral T-cell lymphoma that has come back or not improved after at least one previous treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a new combination of two drugs, SHR2554 and liposomal mitoxantrone, as the first treatment for peripheral T-cell lymphoma (PTCL), a rare type of blood cancer. The goal is to see if this combination is safe and effective.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.